AMA PRA Category 1 Continuing Medical Education TM

 
 
 
 
 
 
 
 
 
Home Page
 
Questions on the course?

.

E-mail US
Call us at 877-626-2220
 
Course Overview
 
Presentation Faculty
 
Course Objectives
 
Cost of the Course
 
Registration Instructions
 
How the Course is Integrated with Computers
 

Access the On-Line Continuing Medical Education Course

 
Privacy and Confidentiality Policy
 
Official Use Only
 
Tahiti by Marty L. Hinz, MD of Cape Coral, FL
 
37.5 Hours of On-line

Continuing Medical Education

 
Management of The Effects of Neurotoxins
 on Neurotransmission
 

Course Overview

  This on-line course has been accredited for 37.5 hours of AMA PRA category 1 continuing medical education. The course is made up of 16 modules ranging in size from 1.5 to 3.75 hours. With each module completed the participant is given credit for the amount of hours accredited for each module is given. When the participant indicates that they have finished a certificate for the number of hours of category 1 continuing medical education completed will be issued.

 

Teaching Both Sides of the Fence

  There is no dispute that neurotoxins can be found in the environment. There is also no dispute that prototype diseases caused by neurotoxins exist. This course teaches "both sides of the fence". On one side of the fence is identification and management of neurotoxin exposure, on the other side of the fence is treating the symptoms of chronic disease caused by neurotoxins.

  This course does not deal with rare patients or disease that may present once or twice in the course of a medical career. This course is about treating medical problems in patients seen on a daily basis in all clinics. If you don't look for the problem you will not find it. One of the goals of this education program is to open the eyes of those that currently do not see the neurotransmission based causes of some of the common diseases  seen in clinics.

  This is not obscure research. The findings of this research project are being published in a series of peer reviewed papers by the University of Minnesota Medical, the first of these papers were published May 1, 2009. On February 7, 2009 Johns Hopkins Medical School published an in-depth peered reviewed writing on this research project.. 

  This continuing medical education course is founded on the writings of these medical schools. This course teaches the first advancement in the monoamine theory in over 60 years. It represents a paradigm shift in previous approaches to treatment under the monoamine theory.

  For optimal results in treatment under this approach training is required. Much of what has been discovered is not intuitive, only manifesting itself in clinical applications through advanced statistical analysis. Training and experience is required. This course will not give mastery of the subject but is a good starting point. Mastery is only acquired once these teachings are applied in clinical practice with a significant number of patients for a significant period of time.

 
 

"This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Board of Quality Assurance and Utilization Review Physicians, Inc. (ABQAURP) and a joint venture between Dr. Alvin Stein and Dr. Marty Hinz.  ABQAURP is accredited by the ACCME to provide continuing medical education for physicians.”

The American Board of Quality Assurance and Utilization Review Physicians, Inc. designates this educational activity for a maximum of 37.5 AMA PRA Category 1 Credit(s)™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

This program is approved for Category 2 credit by the American Osteopathic Association.”
 
Continuing Medical Education